Imperial Oil Limited Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.03 (market cap $25.18B). The key difference: Imperial Oil Limited Common Stock is far larger — about 2.5× Royalty Pharma plc Class A Ordinary Shares's market cap, and Imperial Oil Limited Common Stock pays the higher dividend (1.9%). Which is the better fit depends on your goals.
| IMO | RPRX | |
|---|---|---|
Market Cap | $62.22B | $25.18B |
Volume | 560,544 | 3,399,248 |
Sector | Energy | Health |
52-Week High | $138.33 | $63.96 |
52-Week Low | $83.72 | $36.18 |
Enterprise Value | $63.13B | $32.42B |
Dividend Yield | 1.9% | 1.66% |
Typical Hold Time | — | 6 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Trailing returns across standard periods
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →